Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SEA-CD70 |
Synonyms | |
Therapy Description |
SEA-CD70 is a non-fucosylated monoclonal anti-CD70 antibody that inhibits signaling via CD27, which may lead to enhanced tumor cell killing via antibody-dependent mechanisms and inhibit tumor growth (Blood (2020) 136 (Supplement 1): 23; Blood (2020) 136 (Supplement 1): 23-24). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SEA-CD70 | SEACD70|SEA CD70 | SEA-CD70 is a non-fucosylated monoclonal anti-CD70 antibody that inhibits signaling via CD27, which may lead to enhanced tumor cell killing via antibody-dependent mechanisms and inhibit tumor growth (Blood (2020) 136 (Supplement 1): 23; Blood (2020) 136 (Supplement 1): 23-24). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04227847 | Phase I | SEA-CD70 | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | Recruiting | USA | NLD | 0 |